
Voyant Bio is a biotechnology company that uses AI-powered microscopy and spatial analytics to design precise immunotherapies targeting cancer treatment resistance. Their proprietary platform, Voyant PM, maps immune cell interactions in tumor microenvironments to identify novel therapeutic targets. The company focuses on patients who do not respond to current immunotherapies, aiming to improve cancer treatment outcomes globally. They are part of the Merck Digital Sciences Studio accelerator, receiving strategic guidance and investment to advance their digital drug discovery technologies.

Voyant Bio is a biotechnology company that uses AI-powered microscopy and spatial analytics to design precise immunotherapies targeting cancer treatment resistance. Their proprietary platform, Voyant PM, maps immune cell interactions in tumor microenvironments to identify novel therapeutic targets. The company focuses on patients who do not respond to current immunotherapies, aiming to improve cancer treatment outcomes globally. They are part of the Merck Digital Sciences Studio accelerator, receiving strategic guidance and investment to advance their digital drug discovery technologies.